Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03959891 · ClinicalTrials.gov registry record · Phase 1

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

A Phase 1 study of Breast Cancer, sponsored by Massachusetts General Hospital.

Active
Registry status
Phase 1
Development phase
77
Enrollment target
1
Study location

NCT03959891: Active Phase 1 study of Breast Cancer, sponsored by Massachusetts General Hospital.

NCT03959891 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 77 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03959891, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
77 participants
Enrollment target
1
Study location

Study Summary

This study is exploring the safety/tolerabtility and preliminary efficacy of the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant for patients with metastatic HR+ breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Ipatasertib
  • DRUG Fulvestrant
  • DRUG Palbociclib
  • DRUG Aromatase Inhibitor

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2019-05-30
Est. Completion 2026-07
Phase Phase 1

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03959891

The ClinicalTrials.gov registry entry for NCT03959891 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Ipatasertib is the first listed.

NCT03959891 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03959891 about?

NCT03959891 is a clinical study titled "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)". This study is exploring the safety/tolerabtility and preliminary efficacy of the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant for patients with metastatic HR+ breast cancer.

What is the current status of trial NCT03959891?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2019-05-30. Estimated completion is 2026-07.

What conditions does trial NCT03959891 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03959891?

The interventions under investigation include: Ipatasertib (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG), Aromatase Inhibitor (DRUG).

Who is sponsoring clinical trial NCT03959891?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03959891 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.